The overall trend of lymphocytes following disease refractory to or complicated by multiple lines of treatment. The patient demonstrated rapidly rising LDH and lymphocyte count. Following administration of tofacitinib (red arrow) and ruxolitinib (blue arrow), lymphocyte counts stabilized.